| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.4 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.4 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.048 | 0.4 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |